Low Intratumoral CD200 Protein Expression in Primary Merkel Cell Carcinoma Is a Strong Predictor for Disease Relapse

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with limited treatment options.
• While PD-1/PD-L1 pathways are known immune checkpoints, other modulators like CD200/CD200R are less understood in MCC.
• Elevated CD200 mRNA has been noted in various tumors, suggesting a potential role in immune evasion.

Purpose of the Study:

• To investigate intratumoral protein expression of CD200 and CD200R in a cohort of MCC patients.
• To correlate CD200/CD200R expression levels with clinical outcomes, specifically MCC relapse.
• To explore the CD200/CD200R axis as a potential immune checkpoint in MCC.

Main Methods:

• Multicenter study involving 68 MCC patients (primary tumors and metastases).
• Immunohistochemistry (IHC) was utilized to detect CD200 and CD200R protein expression.
• Digital quantification using QuPath software for objective analysis of IHC results.

Main Results:

• CD200 and CD200R expression was detected in all analyzed MCC samples.
• Low intratumoral CD200 expression was significantly associated with increased MCC relapse risk (HR 9.35, p=0.0007).
• Multivariable analysis identified low CD200 expression (HR 5.25, p=0.0012) and immunosuppression (HR 4.11, p=0.0056) as independent predictors of relapse.

Conclusions:

• CD200/CD200R protein expression is consistently high in MCC, suggesting potential diagnostic utility.
• Low intratumoral CD200 protein expression is a strong, independent predictor of MCC relapse.
• The CD200/CD200R axis warrants further investigation as a therapeutic target in MCC management.